Altor Fund V and Stena Adactum AB have, through the jointly controlled company GB HoldCo AB, announced a recommended cash offer to the shareholders of Gunnebo Aktiebolag. The offer values Gunnebo at approximately SEK 2.4 billion.

Gunnebo develops, manufactures, markets and sells security products, software and services. The Company has its headquarters in Gothenburg with operations globally through own presence in approximately 25 countries. In addition, Gunnebo's products and solutions are sold in more than 100 markets through comprehensive distribution networks.

Vinge’s team consisted of David Andersson, Erik Sjöman, Amanda Knutsson and Julia Hirschberg (Capital Markets and Public M&A), Christina Kokko, Maria Dahlin Kolvik, Desirée Sjöblom, Elsie Nassar and Carl Fredrik Wachtmeister (M&A), Louise Brorsson Salomon, Linn Adelwald, Pauline Lagerstrand and Hannes Pettersson (Banking and Finance) Johan Karlsson and Johan Wahlbom (Competition law), Sofia Bergenstråhle (IP), Karl-Hugo Engdahl (IT) and Jolene Reimerson (Commercial Agreements).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026